#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Toxic epidermal necrolysis Biotinidase deficiency Waldenstrom's macroglobulinaemia refractory Bronchopulmonary dysplasia Cystic fibrosis gastrointestinal disease Pemphigoid Nasopharyngeal cancer Glioma Crohn's disease Amyotrophic lateral sclerosis Optic ischaemic neuropathy Vulval cancer recurrent Chronic graft versus host disease in liver Anaemia Systemic candida More trials…

    Learn about Rare Diseases

    Methylmalonic acidaemia – Treatment Hereditary optic atrophy – Life with Disease Undifferentiated sarcoma – Treatment Splenic marginal zone lymphoma – Basic Information Marfan’s syndrome – Treatment Hairy cell leukaemia – Diagnostics Ewing’s sarcoma metastatic – Trials in Disease Langerhans’ cell histiocytosis Pituitary-dependent Cushing’s syndrome – Trials in Disease Mucopolysaccharidosis III – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cdr132L Sodium GRISNILIMAB SETARITOX Procarbazine Choriogonadotropin Alfa Mk-1200 Nortriptyline Ngi226 Fentanyl Citrate Binimetinib Vidofludimus Calcium Sodium Lactate Solution Opevesostat Gremubamab Vinflunine Etrumadenant Io103 Acetate Polatuzumab Vedotin Afamelanotide Vatiquinone Nafarelin More therapies…

    Learn about Your Condition

    Carcinoid syndrome Friedreich's ataxia Vulval cancer Bladder cancer Red blood cell abnormality Heart disease congenital Pulmonary alveolar haemorrhage Actinic keratosis Mental disorder Ejection fraction normal Traumatic pain Hypersomnia Sarcoidosis Malignant melanoma stage II C3 glomerulopathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Slaskie Centrum Chorob Serca W Zabrzu

Slaskie Centrum Chorob Serca W Zabrzu

Ul. Marii Curie-Sklodowskiej 9, Zabrze, 41-800, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness of Belumosudil and Azithromycin for Adults with Chronic Lung Rejection After Lung Transplant

    Recruiting

    3 1 1
    Investigated Diseases:
    • Lung transplant rejection
    Investigated Drugs:
    • Belumosudil Mesilate
    Austria Belgium Czechia Denmark Finland France +8

  • Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

    Recruiting

    3 1
    Investigated Diseases:
    • Atrial fibrillation
    Investigated Drugs:
    • Abelacimab
    Bulgaria Croatia Czechia Estonia Finland Germany +9

  • Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

    Recruiting

    3 1
    Investigated Diseases:
    • Cardiac failure
    • Obesity
    Bulgaria Czechia Denmark France Germany Greece +4

  • Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

    Recruiting

    3 1
    Investigated Diseases:
    • Acute myocardial infarction
    Investigated Drugs:
    • Selatogrel
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study of Olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

    Not yet recruiting

    3 1
    Austria Belgium Bulgaria Czechia Denmark France +11

  • Study of acetylsalicylic acid and clopidogrel treatment duration after left atrial appendage closure in patients with atrial fibrillation

    Not yet recruiting

    3 1 1 1 1
    Investigated Diseases:
    • Atrial fibrillation
    Investigated Drugs:
    • Clopidogrel
    • Acetylsalicylic Acid
    Poland

  • Study of acetylsalicylic acid and clopidogrel treatment after left atrial appendage closure in patients with atrial fibrillation and chronic kidney disease

    Not yet recruiting

    3 1 1 1 1
    Investigated Diseases:
    • Atrial fibrillation
    Investigated Drugs:
    • Clopidogrel
    • Acetylsalicylic Acid
    Poland

  • Study on Mavacamten for Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Hypertrophic cardiomyopathy
    Investigated Drugs:
    • Mavacamten
    Austria Belgium Czechia Finland France Germany +5

  • A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

    Not recruiting

    3 1
    Austria Belgium Bulgaria Czechia Denmark Estonia +16

  • A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

    Not recruiting

    3 1
    Investigated Drugs:
    • Ziltivekimab
    Austria Belgium Bulgaria Croatia Czechia Denmark +18
Previous Page
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!